For over 50 years, CRA has been a premier consulting firm. Each of our practice areas is highly regarded, and our consultants are recognized for their creative and multi-disciplinary approach to solving our clients’ complex problems in the US and throughout the world.

COVID-19 will have a heterogeneous impact on clinical trials, biopharmas

COVID-19 will have a heterogeneous impact on clinical trials, biopharmas

The novel coronavirus pandemic has created an unprecedented global health crisis.In response to the pandemic, dozens of countries and regions have instituted shelter-in-place orders and some institutions have issued guidelines urging people to minimize non-essential healthcare and/or clinical research.

Impaired access to the healthcare system, travel restrictions, guidance from regulatory agencies, and a shift in resources to fighting the pandemic are beginning to impact the conduct of clinical trials. Angela De Martini, Leandra Plappert, Elizabeth Rountree, and Dean Lockhead held discussions with a selection of CRO, policy, regulatory, and venture capital experts to understand the implications of the pandemic on trials. The authors found that the pandemic will have an immediate (or short-term) impact on the conduct of trials, as well as a long-term impact that may reverberate through the industry in the coming years.

This website uses cookies to improve functionality and performance. If you continue browsing the site, you are giving implied consent to the use of cookies on this website. See our Privacy Policy for details.